The ANRS and the VRI publish a collective work that addresses when HIV-negative individuals agree to participate in a HIV preventive clinical trial. The book is released in the collection "Social Sciences and AIDS" and is available freely on the ANRS website. Yves Lévy and François Dabis signed his preface.
On November 30, 2017, the first conference of the 4 institutes was held in Conakry, Guinea. On the eve of the World Day against HIV / AIDS the subject of this first scientific conference focused on research around HIV and more particularly in Guinea. This meeting was co-organized by the IRD, Inserm, the Pasteur Institute of Guinea and ISPED. Dr Aurélie Wiedemann represented the VRI at this conference, where she spoke on the topic "HIV: the vaccine, a possible prospect?"
The VRI was largely represented at the 9th IAS Conference on HIV with more than 15 oral and/or poster communications by members of the Institute. Yves Lévy (Inserm) spoke in plenary on Monday, July 24, 2017 on "Harnessing the immune system to prevent and control HIV infection". Watch his intervention
We are looking for a qualified and motivated Ph.D. in immunology. The candidate should have a strong experience in flow cytometry, immuno-phenotyping, cell culture, cell sorting and immune functional assays. Basic molecular biology skills and signaling pathways would be a bonus. Excellent technical skills, strong motivation, autonomy and ability to quickly and effectively develop the proposed project in relation with the group leader and collaborators will be essential. Written and spoken English is mandatory.
The French National Institute of Health and Medical Research (Inserm), the US National Institutes of Health (NIH) and the London School of Hygiene & Tropical Medicine (LSHTM), in collaboration with health authorities in Guinea and Liberia, are launching a large clinical trial of candidate Ebola vaccines under the aegis of the PREVAC international consortium (Partnership for Research on Ebola VACcination).
The VRI (“Immunomonitoring-MIC” and “biostatistics & bioinformatics” divisions) is involved in this new clinical trial in Guinea through an immunological sub-study to analyze the immunogenicity of vaccines used in PREVAC.
Result of a collaboration between the CNRS, the VRI, Montpellier University, Inserm, the Institut Pasteur, the Henri-Mondor AP-HP hospital in Créteil, and the Gui de Chauliac hospital (CHU de Montpellier), French researchers have identified a marker that makes it possible to differentiate “dormant” HIV-infected cells from healthy cells. This discovery will make it possible to isolate and analyze reservoir cells which, by silently hosting the virus, are responsible for its persistence even among patients receiving antiviral treatment, whose viral load is undetectable. It offers new therapeutic strategies for targeting infected cells. This research is published in the journal Nature on March 15, 2017.
Today, the International AIDS Society (IAS) announced the plenary speakers and programme for the 9th IAS Conference on HIV Science (IAS 2017). Hosted in partnership with ANRS (The French National Agency for Research on AIDS and Viral Hepatitis), the conference will take place from 23-26 July 2017 in Paris, France.
The plenary program will feature sessions that cover innovative prevention, treatment, and care approaches for HIV. The speakers will spotlight the latest developments in vaccines, cure research for hepatitis B, cancer and immune-based therapies, as well as providing new insights into improved preventative and therapeutic measures.
Yves Lévy (Inserm) will speak about “Harnessing the Immune System to Prevent and Control HIV Infection” on Monday 24th of July 2017
Two candidate vaccines targeting dendritic cells have been developed at the Vaccine Research Institute (VRI), and their manufacture under cGMP guidelines will permit the set-up of future clinical trials in humans.